Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Once-Daily Drug Regimen for HIV-Infected Patients
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00001968
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
- Conditions
- First Posted Date
- 2002-09-19
- Last Posted Date
- 2011-03-01
- Target Recruit Count
- 118
- Registration Number
- NCT00046033
- Locations
- 🇺🇸
Univ of Miami, Miami, Florida, United States
🇺🇸Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Texas, Galveston, Galveston, Texas, United States
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
- Conditions
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00043888
- Locations
- 🇬🇧
GSK Clinical Trials Call Center, Manchester, United Kingdom
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 69
- Registration Number
- NCT00040664
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers
- Conditions
- First Posted Date
- 2002-06-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 32
- Registration Number
- NCT00039975
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
- Conditions
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 36
- Registration Number
- NCT00038636
- Locations
- 🇪🇸
Hospital Clinico de Barcelona, Barcelona, Spain
🇪🇸Ciutat Sanitaria de Bellvitge, Barcelona, Spain
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine
- Conditions
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00001688
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
- Conditions
- First Posted Date
- 2001-12-28
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 56
- Registration Number
- NCT00028366
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
- Conditions
- First Posted Date
- 2001-12-05
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 53
- Registration Number
- NCT00027339
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸Beth Israel Med. Ctr., ACTU, New York, New York, United States
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
- Conditions
- First Posted Date
- 2001-10-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 330
- Registration Number
- NCT00025727
- Locations
- 🇺🇸
Bach and Godofsky, Bradenton, Florida, United States
🇺🇸Therafirst Med Ctr, Fort Lauderdale, Florida, United States
🇺🇸Rush Med College / Dept of Infectious Diseases, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.